Nutex Health Inc

Nutex Health has secured approval to dual-list its common stock on Nasdaq Texas, with trading expected to begin around September 23, 2026, a move the company says may broaden liquidity and investor access. The approval comes as the most followed analyst narrative values Nutex Health at $283.00 per share, roughly 29% above its last close of $201.86. That narrative rests on arbitration-related revenue, which currently accounts for more than 60% of the company's total, and on regulatory clarity around the No Surprises Act and the IDR process, including proposed legislation to enforce penalties for payer nonpayment. Cost discipline through vertical integration with physician groups and technology investments such as AI-driven workflows has pushed general and administrative costs down to 4.9% of revenue, which the narrative says could support sustained net margin expansion as scale increases. The story remains exposed to regulatory change or execution slips, particularly around arbitration-driven revenue and new facility rollouts.

Nutex Health reported a second-quarter 2026 net income of $65.8 million, or $9.38 per diluted share, reversing a net loss of $17.7 million a year earlier. A favorable amendment to the company's agreement with HaloMD and a reduction in the CMS administrative fee for the federal Independent Dispute Resolution process cut contract services expenses by $52.3 million during the quarter. Hospital division visits increased 9.6% year over year to 49,962, while same-hospital visits rose 6.3%. Total revenue declined 13.6% to $210.8 million, which the company attributed to favorable early-stage IDR improvements realized in the first half of 2025. Nutex Health ended the quarter with $205.2 million in cash and $31.1 million in long-term debt, and expects to open three new hospitals later in 2026.

Nutex Health saw its revenue triple and profit grow nearly twelvefold after it began filing arbitration disputes under the No Surprises Act, according to a STAT report on June 29. The development highlights how the company's microhospital model ties performance closely to reimbursement outcomes and payer disputes. Analysts have an average price target implying about 25.4% upside for the stock, though wider target dispersion makes the risk-reward profile less straightforward. The upside case depends on whether Nutex can sustain profitability while navigating scrutiny around out-of-network billing and reimbursement rules.